“TRACKING HER2 TRAFFICKING AND ORGANELLE CROSSTALK IN TRASTUZUMAB-DERUXTECAN–TREATED BREAST CANCER CELLS USING MULTIMODAL IMAGING: E. Tagliatti1, M. C. Gagliani2, G. Bellese2, M. Crippa3, A. Abbona4, M. Paccagnella4, P. Arnaldi5, M. C. Merlano6, O. Garrone7, A.M. Porcelli8, M. Matteoli1, P. Falletta9, P. Castagnola10, K. Cortese2 | 1IRCCS Humanitas Research Hospital, Laboratory of Pharmacology and Brain Pathology, Rozzano, Milano, Italy; 2DIMES, Department of Experimental Medicine, Cellular Electron Microscopy Lab, University of Genoa, Genoa, Italy; 3Experimental Imaging Center, IRCCS Ospedale San Raffaele, Milan, Italy; 4Health Department S. Croce e Carle Teaching Hospital, Cuneo, Italy; 5IRCCS Ospedale Policlinico San Martino, Genova, Italy; 6Scientific Direction, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; 7Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 8FABIT, Department of Pharmacy and Biotechnology and CIRI, Interdepartmental Centre for Industrial Research ‘Scienze Della Vita e Tecnologie per La Salute’, University of Bologna, Bologna, Italy; 9Vita-Salute San Raffaele University, Milan, Italy; 10IRCCS Ospedale Policlinico San Martino, Genova, Italy” (2025) European Journal of Histochemistry, 69(s2). doi:10.4081/ejh.2025.4305.